Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors.

Martina S J McDermott Neil A O'Brien Benjamin Hoffstrom Ke Wei Gong Ming Lu Jun Zhang Tong Luo Min Liang Weiping Jia Jenny Hong Kevin Chau Simon Davenport Bin Xie Michael F Press Richard Panayiotou Abram Handly-Santana Joan S Brugge Leonard Presta John A Glaspy Dennis J Slamon

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

We report the development of a novel antibody-drug conjugate, CLDN6-23-ADC, that selectively targets CLDN6, a potential onco-fetal-antigen which is highly expressed in ovarian and endometrial cancers. CLDN6-23-ADC exhibits robust tumor regressions in mouse models of human ovarian and endometrial cancers and is currently undergoing Phase I study.

Keyphrases

diffusion weighted imaging
diffusion weighted
endothelial cells
mouse model
endometrial cancer
cancer therapy
magnetic resonance imaging
stem cells
computed tomography
mesenchymal stem cells
cell therapy
young adults
climate change
induced pluripotent stem cells
bone marrow
human health